Table 1. Factors that showed a predominant association with ischaemic stroke or myocardial infarction (RRR>1+SE and RRR<1-SE).
| RRR>1+SE | RRR<1-SE | ||||
|---|---|---|---|---|---|
| ID | Coagulation factor (contrast) | RRR (95% CI) | ID | Coagulation factor (contrast) | RRR (95% CI) |
| Pro-coagulant | |||||
| 317 | FXIIIA SNP Tyr204phe (dominant) * | 11.1 (5.64–21.82) | 53 | fibrinopeptide A (T3 vs T1) | 0.63 (0.31–1.26) |
| 282 | FVIII SNP 165293 rs6655259 (allele) * | 4.72 (0.62–35.73) | 301 | FXIIIA SNP Pro564Leu (dominant) | 0.64 (0.31–1.29) |
| 331 | FXIIIA SNP Val34Leu (L/L vs V/V) * | 4.66 (0.44–49.1) | 121 | FGA 3807 (allele) | 0.77 (0.52–1.12) |
| 281 | FXIIIA SNP 177424 (allele) * | 3.71 (0.62–22.35) | 123 | FX SNP 9501 (allele) | 0.77 (0.51–1.17) |
| 294 | FV Leiden (dominant) | 3.42 (0.11–104) | 284 | fibrinogen (SD) | 0.78 (0.61–0.98) |
| 280 | FVIII SNP 25167 (allele) * | 2.8 (0.7–11.2) | 128 | FXI SNP 3450 (allele) | 0.81 (0.59–1.11) |
| 315 | FXIa-C1-INH (>90 percentile)* | 2.58 (0.77–8.72) | |||
| 313 | FXIIa-C1-INH (>90 percentile) * | 2.53 (0.74–8.6) | |||
| 105 | FV Leiden (allele) * | 2.44 (0.6–10) | |||
| 310 | FXIa-AT-INH (>90 percentile) * | 2.32 (0.68–7.95) | |||
| 104 | FV SNP Rs7542281 (allele) | 2.22 (0.65–7.56) | |||
| 307 | FXIIIB SNP His95Arg (dominant) * | 2.15 (0.88–5.25) | |||
| 64 | d-dimer (SD (log scale)) * | 1.88 (0.81–4.4) | |||
| 278 | FVIII SNP 95826 (allele) * | 1.81 (1.02–3.2) | |||
| 102 | FV SNP Rs6035 (allele) | 1.74 (0.56–5.4) | |||
| 277 | FXI SNP 4197 (allele) | 1.58 (0.61–4.1) | |||
| 276 | FVIII SNP 55941 (allele) | 1.5 (0.9–2.5) | |||
| 275 | FV SNP upper 38592 (allele) | 1.49 (0.69–3.21) | |||
| 63 | fibrinogen (SD (log scale)) * | 1.46 (0.96–2.22) | |||
| 274 | FVIII SNP 139972 (allele) | 1.45 (0.68–3.08) | |||
| 37 | d-dimer (T3 vs T1) | 1.44 (0.63–3.32) | |||
| 100 | FV SNP Rs3753305 (allele) | 1.39 (0.67–2.86) | |||
| 347 | trombin generation (PEAK) (SD) | 1.27 (0.83–1.95) | |||
| 269 | FXIIIA SNP 4377 (allele) | 1.26 (0.93–1.71) | |||
| 268 | FX SNP 4544 (allele) | 1.25 (0.83–1.87) | |||
| 267 | FGA 5498 (allele) | 1.25 (0.84–1.86) | |||
| 265 | FXI SNP 10942 (allele) | 1.22 (0.83–1.78) | |||
| 264 | FV SNP lower 29565 (allele) | 1.21 (0.87–1.69) | |||
| 262 | TFPI SNP 2418 (allele) | 1.17 (0.9–1.51) | |||
| 260 | FGA 251 (allele) | 1.15 (0.87–1.52) | |||
| Anticoagulant | |||||
| 103 | prot C SNP Rs2069920 (allele) | 1.92 (0.93–3.96) | 71 | thombomodulin SNP Rs3176123 | 0.62 (0.3–1.28) |
| 13 | prot C (Q1 vs Q5) * | 1.65 (1.05–2.6) | 118 | prot C receptor SNP 837 (allele) | 0.74 (0.46–1.2) |
| 101 | prot C SNP Rs1401296 (allele) * | 1.42 (0.67–3.03) | 127 | thombomodulin SNP 6235 (allele) | 0.81 (0.58–1.13) |
| 266 | prot C SNP 11310 (allele) | 1.22 (0.92–1.62) | 130 | prot C SNP 4515 (allele) | 0.83 (0.63–1.1) |
| Fibrinolysis | |||||
| 314 | CLT (hypo vs. normofibrinolysis) * | 2.54 (0.71–9.09) | 350 | t-PA (Q4 vs Q1) | 0.44 (0.17–1.15) |
| 329 | PAI-1 SNP 4G/5G (4G/5G vs 4G/4G) | 2.12 (0.51–8.69) | 125 | t-PA SNP 30619 (allele) | 0.78 (0.51–1.18) |
| 20 | TAFI SNP 1040C/T (CC vs TT) | 1.79 (0.45–7.11) | 129 | plasminogen SNP 18114 (allele) | 0.83 (0.63–1.11) |
| 326 | PAI-1 SNP 4G/5G (allele) | 1.68 (0.45–6.24) | 131 | TAFI SNP 54691 (allele) | 0.83 (0.61–1.12) |
| 341 | t-PA (SD) | 1.54 (0.55–4.34) | |||
| 22 | t-PA (T3 vs T1) | 1.5 (0.69–3.27) | |||
| 62 | t-PA (SD (log scale)) | 1.35 (0.81–2.25) | |||
| Other | |||||
| 316 | lupus anticoagulant (ratio > = 1.15) 1 * | 8.13 (0.61–108) | 24 | whole blood aggregation (Q5 vs Q1) | 0.25 (0.07–0.93) |
| 330 | GPIb SNP thr/Met (recessive) | 2.55 (0.48–13.69) | 25 | PLT aggregation (first) (Q5 vs Q1) | 0.49 (0.18–1.31) |
| 312 | KAL-C1-INH (>90 percentile) * | 2.42 (0.77–7.64) | 70 | ICAM1 SNP Rs3093030 (allele) | 0.55 (0.26–1.17) |
| 311 | anti-beta2GP (>95 percentile) | 2.33 (0.63–8.71) | |||
| 309 | anti-prothrombin IgG (>95 percentile) | 2.25 (0.38–13.5) | |||
| 308 | ADAMTS-13 (Q1 vs Q4) | 2.21 (0.65–7.51) | |||
| 327 | GPIa SNP C807T (recessive) | 1.78 (0.45–7.04) | |||
| 23 | VWF (T3 vs T1) | 1.56 (0.72–3.34) | |||
(1) Normalised ratios for LA-screen and LA-confirm coagulation times. The positivity for lupus anticoagulant was considered when the ratio was 1.15 or higher, on the basis of the 99th percentile of the value recorded for 40 healthy volunteers. More details can be found in the original publication.
(*) Prothrombotic factors with an RRR greater than 1+2SE. No prothrombotic factor had an RRR less than 1-2SE.